Drug Profile
Research programme: carbonyl-trapping agents - Secant Pharma/Avalo Therapeutics
Latest Information Update: 30 Aug 2021
Price :
$50
*
At a glance
- Originator Secant Pharma LLC
- Class
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis; Diabetes mellitus; Diabetic complications; Inflammation; Neurological disorders; Osteoporosis
Most Recent Events
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 17 Nov 2017 TRx Pharma has been acquired and merged into Cerecor
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)